Physician
Hanover Pediatric Associates, P.C.
Hanover Pediatric Associates, P.C. was paid $2.70M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider infoHANOVER PEDIATRIC ASSOCIATES, P.C.
HANOVER, PA 17331
HANOVER, PA 17331
33aNPI1891721064assigned 06/23/2006
33bProvider typePediatrics Physician
28Total paid$2.70M
24GClaims136,057
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Pennsylvania
Rank by total paid#28 of 1,257
Median peer was paid$45K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 838 | $40K | |
| 2019 | 573 | $19K | |
| 2020 | 3,535 | $94K | |
| 2021 | 31,266 | $626K | |
| 2022 | 34,346 | $653K | |
| 2023 | 35,519 | $668K | |
| 2024incomplete | 29,980 | $600K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 25,496 | 22,421 | $929K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 12% | 3,980 | 3,847 | $331K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 9.8% | 3,354 | 3,259 | $265K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.6% | 2,389 | 2,280 | $204K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.5% | 4,042 | 3,730 | $203K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.6% | 1,972 | 1,898 | $151K |
| 99051 | 4.4% | 3,514 | 3,364 | $119K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.3% | 3,355 | 3,251 | $115K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.8% | 6,699 | 3,269 | $75K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.0% | 6,029 | 5,715 | $54K |
| 92551 | 1.5% | 7,036 | 6,781 | $41K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.5% | 1,125 | 1,081 | $40K |
49 more codes
| 87081 | <1% | 4,816 | $24K | |
| 99173 | <1% | 6,015 | $24K | |
| 87634 | <1% | 287 | $19K | |
| 90686 | <1% | 2,237 | $16K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 303 | $8K |
| D0120 | Dental checkup, returning patient | <1% | 376 | $8K |
| 87428 | <1% | 241 | $7K | |
| 90648 | <1% | 2,143 | $6K | |
| 99188 | <1% | 439 | $6K | |
| 90670 | <1% | 1,541 | $6K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 462 | $5K |
| 92015 | Determination of refractive state | <1% | 939 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 266 | $4K |
| 90723 | <1% | 1,078 | $4K | |
| 90680 | <1% | 1,377 | $4K | |
| 90633 | <1% | 1,178 | $3K | |
| 90710 | <1% | 1,172 | $3K | |
| 96127 | <1% | 2,982 | $3K | |
| 80061 | Lipid panel | <1% | 1,406 | $3K |
| 87807 | <1% | 160 | $2K | |
| 96160 | <1% | 2,722 | $2K | |
| 94760 | <1% | 9,087 | $2K | |
| 90734 | <1% | 737 | $1K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,979 | $1K |
| 90715 | <1% | 821 | $1K | |
| 81003 | <1% | 387 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 16 | $1K |
| 90696 | <1% | 378 | $880.00 | |
| 83655 | <1% | 4,751 | $552.71 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 45 | $462.32 |
| 90651 | <1% | 404 | $370.00 | |
| 85018 | <1% | 999 | $341.46 | |
| 90620 | <1% | 212 | $253.84 | |
| 90700 | <1% | 180 | $231.00 | |
| A7006 | Administration set, with small volume filtered pneumatic nebulizer | <1% | 64 | $207.12 |
| 96161 | <1% | 1,436 | $194.32 | |
| 90461 | <1% | 29 | $183.74 | |
| 92567 | <1% | 12 | $118.32 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 74 | $3.12 |
| 36416 | <1% | 1,007 | $2.73 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 56 | $0.32 |
| 3078F | 0% | 4,704 | $0.00 | |
| 90672 | 0% | 14 | $0.00 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 13 | $0.00 |
| 3074F | 0% | 4,808 | $0.00 | |
| D9999 | Unspecified adjunctive procedure, by report | 0% | 632 | $0.00 |
| 85013 | 0% | 200 | $0.00 | |
| 90677 | 0% | 524 | $0.00 | |
| 90656 | 0% | 357 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMASUCCI, DOUGLAS (PRESIDENT)